Safety Assessment of PCA and Its Salts as Used in Cosmetics

Status:	Re-Review for Panel Review
Release Date:	August 18, 2014
Panel Meeting Date:	September 8-9, 2014

The 2014 Cosmetic Ingredient Review Expert Panel members are: Chairman, Wilma F. Bergfeld, M.D., F.A.C.P.; Donald V. Belsito, M.D.; Ronald A. Hill, Ph.D.; Curtis D. Klaassen, Ph.D.; Daniel C. Liebler, Ph.D.; James G. Marks, Jr., M.D., Ronald C. Shank, Ph.D.; Thomas J. Slaga, Ph.D.; and Paul W. Snyder, D.V.M., Ph.D. The CIR Director is Lillian J. Gill, D.P.A. This safety assessment was prepared by Monice M. Fiume, Assistant Director/Senior Scientific Analyst.

1620 L Street, NW, Suite 1200 ♢ Washington, DC 20036-4702 ♢ ph 202.331.0651 ♢ fax 202.331.0088 ♢
cirinfo@cir-safety.org

Memorandum

To: CIR Expert Panel Members and Liaisons
From: Monice M. Fiume MMF
Assistant Director/Senior Scientific Analyst
Date: August 18, 2014
Subject: Safety Assessment of PCA and Its Salts as Used in Cosmetics

Enclosed is the Re-Review of the Safety Assessment on PCA and Its Salts as Used in Cosmetics. (It is identified as *PCA092014rep_final for posting* in the pdf document.) In 1999, the Panel concluded that PCA and sodium PCA were safe as used in cosmetics, and that these ingredients should not be used in cosmetic products containing nitrosating agents. Three previously un-reviewed salts of PCA, i.e., calcium PCA, magnesium PCA, and potassium PCA, are being proposed for addition to this group.

The Panel is now being asked to consider whether a re-review of this ingredient group is appropriate. The Panel should first determine whether the new data serve to reaffirm the existing conclusion, or, if they present a reason to reassess the safety of these ingredients. Much of the new data included in this safety assessment was found on the European Chemicals Agency (ECHA) website; as a reminder, the website provides summaries of information generated by industry, and it is those summary data that are included.

Secondly, three additional salts (calcium, magnesium, and potassium PCA) are being suggested for addition to this family. If the Panel agrees that the data in the existing report, as well as the new data presented in this re-review document, support the safety of these proposed ingredients, the Panel should re-open this assessment to add these ingredients.

Concentration of use data were received from the Council and are included for your review (*PCA092014data*). (Also included are updated VCRP data, *PCA092014FDA*.) You will note that the frequency of use of these ingredients has increased, and the concentration of use has increased slightly. Additionally, the original safety assessment is provided (*PCA092014prev*).

Several outcomes are possible based on Panel review of this re-review document:

1. The Panel determines that the new data do not support the existing conclusion, and the report is re-opened to address these concern;
2. The Panel determines that the new data support the existing conclusion, and new and existing data also support the safety of the proposed "add-ons;" the Panel should issue a Tentative Amended Report that includes the new ingredients; or
3. The Panel determines that the new data support the existing conclusion, but the proposed "add-ons" are not "no-brainers" and are not appropriate for inclusion in the report; the Panel should reaffirm the existing conclusion, and not re-open the report.

PCA RR

SAFETY ASSESSMENT FLOW CHART

Sept 2014



*The CIR Staff notifies of the public of the decision not to re-open the report and prepares a draft statement for review by the Panel. After Panel review, the statement is issued to the Public.

**If Draft Amended Report (DAR) is available, the Panel may choose to review; if not, CIR staff prepares DAR for Panel Review.

PCA and Its Salts – History

1999: The Panel concluded PCA and sodium PCA are safe as used in cosmetics, and that these ingredients should not be used in cosmetic products containing nitrosating agents.

September 8-9, 2014, Draft Report: initial review of the re-review. Calcium PCA, magnesium, PCA, and potassium PCA are being proposed for addition in this group. Data available since the original review are included in the report; these data were found on the ECHA website.

Unpublished concentration of use data were included in the document.

PCA and Its Salts – Sept 2014 – Monice Fiume																			
	Reported Use	**Method of Mfg**	**Toxicokinetics**	**Percutaneous Absorption**	**Animal Tox – Acute, Dermal**	**Animal Tox – Acute, Oral**	**Animal Tox, Acute, Inhal.**	**Animal Tox – Rptd Dose, Derm**	**Animal Tox, Rptd Dose, Oral**	**Human – Rptd Dose, Oral**	**Animal Tox – Rptd Dose, Inhal**	**Repro/Dev Tox**	**Genotox**	**Carciniogenicity**	**Photocarc**	**Dermal Irr/Sens**	**Phototoxicity**	**Ocular Irritation**	**Mucous Membrane Irr**
PCA	X*	*	*						*				*					*	
Sodium PCA	X*		*	*	X	X*			*			X	X*			X*	*		X*
Calcium PCA	X																		
Magnesium PCA	X																		
Potassium PCA	X																		

"X" indicates that new data were available in a category for the ingredient
"*" indicates that existing data are summarized for the ingredient

PCA – ReReview

PCA
149-87-1, DL-
98-79-3

Sodium PCA
54571-67-4, DL-
28874-51-3, L-

Calcium PCA
31377-05-6

Magnesium PCA
5819-47-6

Potassium PCA
4810-50-8

Search Terms

PubMed (July 14, 2014)

(((((((149-87-1[EC/RN Number]) OR 98-79-3[EC/RN Number]) OR 54571-67-4[EC/RN Number]) OR 28874-51-3[EC/RN Number]) OR 31377-05-6[EC/RN Number]) OR 5819-47-6[EC/RN Number]) OR 4810-50-8[EC/RN Number]) AND (ALL TOXICOKINETIC* OR ALL TOXIC* OR ALL TOXICITY OR ALL IRRITA* OR ALL SENSITIZ* OR ALL PHOTOTOX* OR ALL GENOTOXIC* OR ALL MUTAGEN* OR ALL CARCINOGEN* OR ALL TERATOGEN* OR ALL REPRODUCT* OR ALL ESTROGEN* OR ALL DERMAL) – 327/0 useful

((((((149-87-1[EC/RN Number]) OR 98-79-3[EC/RN Number]) OR 54571-67-4[EC/RN Number]) OR 28874-51-3[EC/RN Number]) OR 31377-05-6[EC/RN Number]) OR 5819-47-6[EC/RN Number]) OR 4810-50-8[EC/RN Number] – 2476 hits/1 useful

Also searched ECHA, HPV/SIDS, CFR, EU,ChemPortal.

Safety Assessment of PCA and Its Salts as Used in Cosmetics

Status:	Re-Review for Panel Review
Release Date:	August 18, 2014
Panel Meeting Date:	September 8-9, 2014

The 2014 Cosmetic Ingredient Review Expert Panel members are: Chairman, Wilma F. Bergfeld, M.D., F.A.C.P.; Donald V. Belsito, M.D.; Ronald A. Hill, Ph.D.; Curtis D. Klaassen, Ph.D.; Daniel C. Liebler, Ph.D.; James G. Marks, Jr., M.D., Ronald C. Shank, Ph.D.; Thomas J. Slaga, Ph.D.; and Paul W. Snyder, D.V.M., Ph.D. The CIR Director is Lillian J. Gill, D.P.A. This safety assessment was prepared by Monice M. Fiume, Assistant Director/Senior Scientific Analyst.

1620 L Street, NW, Suite 1200 ♢ Washington, DC 20036-4702 ♢ ph 202.331.0651 ♢ fax 202.331.0088 ♢
cirinfo@cir-safety.org

INTRODUCTION

In 1999, the Cosmetic Ingredient Review (CIR) Expert Panel (Panel) published a safety assessment of PCA and sodium PCA.[1] Based on the data presented in that assessment, the Panel concluded that these ingredients are safe as used in cosmetic formulations; additionally, these ingredients should not be used in cosmetic products containing *N*-nitrosating agents.

The Panel is now being asked to consider a re-review of the safety of PCA and sodium PCA. In addition to these two ingredients, an additional three previously un-reviewed salts of PCA are being proposed for addition to this group. Upon approval by the Panel, the five ingredients included in this re-review are:

PCA
Sodium PCA
Calcium PCA
Magnesium PCA
Potassium PCA

These five ingredients are reported to function as skin conditioning agents – humectant in cosmetic formulations[2] (Table 1).

The complete original report on PCA can be found on the CIR website, http://www.cir-safety.org/ingredients. Therefore, only excerpts from the Summary of the original report will be included, as appropriate; the excerpted information will be identified by *italicized text*. Please refer to the original report for detailed information.

All of the new data included in this safety assessment were found on the European Chemicals Agency (ECHA) website.[3] The ECHA website provides summaries of information generated by industry, and it is those summary data that are reported in this safety assessment when ECHA is cited. Unless indicated otherwise in this assessment, all of the ECHA data pertains to the L-form of sodium PCA.

CHEMISTRY

Definition and Structure

PCA is more commonly known as pyroglutamic acid.[1] It is an internal amide of L-glutamic acid found in vegetables, fruits, grasses, and molasses.

The definitions and structures of PCA (2-pyrrolidone-5-carboxylic acid) and its salts are provided in Table 1.

Chemical and Physical Properties

PCA is an orthorhombic bisphenoidal crystal with a molecular weight of 129.11.[1] It is soluble in water, alcohol, and acetone. PCA is non-hygroscopic, but its sodium salt is extremely hygroscopic. The ultraviolet (UV) absorption spectrum of PCA indicates very weak absorption from 320-240 nm and strong absorption from 240 nm to shorter wavelength.

Nitrosation

The [N-]nitrosation of PCA was investigated under conditions simulating those in the stomach following a meal.[1] PCA was reacted with sodium nitrite at pH 2.5 and 37°C, and sulfamic acid was added to the mixture. The initial rate of reaction was very slow and the rate constant was 1.23 x 10-3 M^{-1} min^{-1}. The investigators noted that this rate value was 1.7% of that observed with hydanoic acid and 0.03% of that of nitrosomethylurea formation.

Methods of Manufacture

PCA is prepared from L-glutamic acid by autoclaving with an equal weight of water at 135-140°C.[1]

Impurities

No by-products are reported in the production of PCA and sodium PCA from glutamic acid and sodium glutamate, respectively.[1] It could be expected that some dimer or polymer of glutamic acid would be found, but none was detected with carnet analytical methods. However, glutamic acid and sodium glutamate are possible impurities.

Natural Occurrence

PCA is a naturally occurring component of mammalian tissue; 270 µmol/g wet weight was found using ion exchange chromatography in epidermal scrapings taken from albino guinea pigs.[1] In further studies with epidermal samples from guinea pigs, humans, dogs, rats, and mice, the total amount of free PCA was 186.0, 44.9, 30.9, 21.3, and 19.0 µmol/g wet weight, respectively. Optical rotatory dispersion studies of PCA isolated from guinea pig skin indicated that the epidermal PCA was the L isomer. The concentration of PCA in other tissues of guinea pigs was much lower than that found in the epidermis.

L-PCA is also present in the human epidermis at approximately 16.5 mg/g fresh tissue and in normal human plasma at approximately 21.6 µmol/100 ml plasma. Free PCA is also found in the cerebrospinal fluid as the L-isomer and in the urine as both the L- and D-isomers. PCA (and sodium lactate) constitute the most hygroscopic fraction of the stratum corneum.

USE

Cosmetic

PCA and its salts are reported to function in cosmetics as skin conditioning agents - humectants[2] (Table 1). The intended use of ingredients that function as humectant skin-conditioning in cosmetics is to increase the water content of the top layers of skin.

The Food and Drug Administration (FDA) collects information from manufacturers on the use of individual ingredients in cosmetic formulations as a function of cosmetic product category in its Voluntary Cosmetic Registration Program (VCRP). VCRP data obtained from the FDA in 2014[4] and data received in response to a survey of the maximum reported use concentration by category conducted by the Personal Care Products Council (Council)[5] indicate that PCA and its salts are being used in cosmetic formulations. Sodium PCA has the most reported uses and the highest concentration of use; it is reported to be used in 1289 formulations, and the maximum leave-on and rinse-off concentrations of use are 2.5% in nail creams and lotions and 3% in skin cleansing preparations, respectively (Table 2). PCA is currently reported to be used in 106 formulations, and the maximum concentration of use is 1.9% in face powders. The frequency of use of these ingredients has increased since the original safety assessment, but the concentration of use has not changed much; at that time, PCA was used in 25 formulations and sodium PCA in 437, and the maximum use reported was 2.5% PCA and sodium PCA in a moisturizer.

The calcium, magnesium, and potassium salts of PCA are used less frequently and at lower concentrations (i.e., less than 0.75%) (Table 3).

Many of the reported uses are in the eye area; the highest concentration of use reported for eye products is 2% sodium PCA in an eye lotion. According to VCRP data, sodium PCA is used in five baby products, however, concentration of use data were not reported for this use category. Use in products applied to the mucous membranes or in products that could possibly be ingested have also been reported at low concentrations.

Additionally, PCA and sodium PCA are used in cosmetic sprays and could possibly be inhaled; for example, sodium PCA is used at up to 0.2% in pump hair sprays and PCA is used at up to 1.9% in face powders. In practice, 95% to 99% of the droplets/particles released from cosmetic sprays have aerodynamic equivalent diameters >10 μm, with propellant sprays yielding a greater fraction of droplets/particles <10 μm compared with pump sprays.[6,7] Therefore, most droplets/particles incidentally inhaled from cosmetic sprays would be deposited in the nasopharyngeal and thoracic regions of the respiratory tract and would not be respirable (i.e., they would not enter the lungs) to any appreciable amount.[8,9] There is some evidence indicating that deodorant spray products can release substantially larger fractions of particulates having aerodynamic equivalent diameters in the range considered to be respirable.[9] However, the information is not sufficient to determine whether significantly greater lung exposures result from the use of deodorant sprays, compared to other cosmetic sprays.

PCA and its salts are listed in the European Union inventory of cosmetic ingredients.[3]

TOXICOKINETICS

The major pathway by which L-PCA is formed involves the catalysis of y-glutamyl amino acids by y-glutamyl cyclotransferase.[1]

The percutaneous absorption of 5, 10, and 20% sodium PCA through fresh human cadaver skin in a 24-h period was 5.97, 6.78, and 5.89%, respectively. PCA was present in the plasma and brain of rats following oral administration. In studies with rabbits and mice, it was reported that PCA was metabolized into glutamic acid and y-aminobutyric acid. A study using dogs reported that of the 70% of the oral dose absorbed, 30% was eliminated unchanged in the urine and the remainder was converted to urea. PCA given subcutaneously was also rapidly metabolized in mice.

The amount of exogenously applied PCA absorbed through the skin was on the order of 1% of the applied dose, but up to 5% was distributed between the dermis and epidermis.

TOXICOLOGICAL STUDIES

The oral LD_{50} of sodium PCA was 10.4 g/kg for male mice and >2.0 g/kg for a 50% solution in a study with rats.[1] *No adverse effects were observed in either a short-term study using rats fed 1.5% PCA or in subchronic studies with rats fed diets containing up to 8% PCA. In a study using mice, PCA was neurotoxic when injected intrastriatally. However, no effects were observed in a similar study with rats or after oral administration to mice.*

In the original safety assessment, the Panel recognized that although sodium PCA was reported to be used in aerosol products, there was a lack of inhalation toxicity data. The Expert Panel noted that PCA is structurally similar to 4-hydroxy-L-proline, a major component of mammalian collagen. Also important was the minimal, transient ocular irritation produced by 50% sodium PCA, which is used in hair sprays. The Expert Panel considered that such a compound, then, is unlikely to elicit a serious toxicological effect if inhaled as a result of an exposure to hair spray. Based on the structure of the ingredient and the existing data included in this report, the Expert Panel did not envision that sodium PCA would be a respiratory irritant and therefore did not require inhalation toxicity data to make a determination of safety.

Single Dose (Acute) Toxicity

Dermal

Occlusive patches with 2 g/kg undiluted sodium PCA were applied to the backs of five male and five female rats for 24 h.[10] No mortality was reported, and the dermal LD_{50} in rats was >2 g/kg.

Oral

Two groups of three female rats were given a single dose by gavage of 2 g/kg sodium PCA in distilled water.[10] None of the animals died, and the oral LD_{50} in rats was >2 g/kg.

REPRODUCTIVE AND DEVELOPMENTAL TOXICITY

In the original safety assessment, the Panel was concerned that developmental toxicity data were absent.[1] The Panel determined that a safety assessment could be completed, however, if PCA was found not to significantly penetrate the skin. Data were made available indicating that the amount of exogenously applied PCA absorbed through the skin was on the order of 1% of the applied dose, but that up to 5% was distributed between the dermis and epidermis. Concern was expressed over the potential that the PCA adsorbed in the dermis and epidermis would eventually move across the skin and result in a cumulative penetration that could be significant. This concern was mitigated by the low actual penetration through the skin over a 24-hour period and the recognition that PCA is naturally resident in the skin. Additionally, it was noted that adverse effects were absent in a 26-week oral study. With these factors considered, the Expert Panel concluded that the extent of penetration was not significant and that developmental toxicity data were not critical to completion of the safety assessment.

Sodium PCA was not a developmental or reproductive toxicant in rats.[10] Groups of 12 male and 12 female Wistar rats were dosed by gavage once daily with 0, 62.5, 250, or 1000 mg/kg bw/day sodium PCA in water. The females were dosed for 2 wks prior to mating until day 4 of lactation; the males were dosed for 14 days prior to mating and for 14 days during mating. No adverse effects on any measured parameters in the parents or offspring were observed. The no-observable adverse effect level (NOAEL) for maternal and reproductive toxicity was 1000 mg/kg bw/day.

GENOTOXICITY

PCA and sodium PCA were not mutagenic in a Salmonella mutagenicity assay with or without metabolic activation, and PCA was not considered clastogenic in a chromosome damage assay.[1]

Sodium PCA in distilled water was not genotoxic in an Ames test, mammalian cell gene mutation assay, or chromosomal aberration assay, with or without metabolic activation.[10] In the Ames test, *Salmonella typhimurium* strains TA1535, TA1537, TA98, and TA 100, and *Escherichia coli* stain WP2 uvrA were exposed to 78.125-5000 µg/plate. Mouse lymphoma L5178Y cells were exposed to 20.58-5000 µg/ml in the mammalian cell gene mutation assay, and Chinese hamster lung fibroblasts V79 cells were exposed to 312.5-5000 µg/ml in the chromosomal aberration assay. Appropriate solvent and positive controls gave valid results in each study.

CARCINOGENICITY

Carcinogenicity data were not found in the published literature, nor were unpublished data provided.

IRRITATION AND SENSITIZATION

Dermal Irritation and Sensitization

In Vitro

Undiluted sodium PCA was considered to be non-irritating in a reconstructed human epidermis model test using the EpiSkin model.[10] Twenty mg of the test article was applied to the skin model for 15 min.

Non-Human

Sodium PCA was non-irritating when applied to the skin of guinea pigs and rabbits at concentrations up to 50%.[1] No evidence of dermal sensitization was observed when guinea pigs were induced with 2-50% aq. sodium PCA and challenged with 5% aq. sodium PCA. Sodium PCA was non-comedogenic in rabbits.

Sodium PCA was not a sensitizer in a guinea pig maximization test (GPMT).[10] Ten female Hartley guinea pigs were exposed to 20% aq. sodium PCA at both intradermal and epidermal induction. Intradermal induction involved paired injections of 0.1 ml Freund's complete adjuvant (FCA), 0.1 ml of the test solution, and 0.1 ml of the test material and FCA. Four days later, 10% sodium lauryl sulfate in petrolatum was applied to the skin of the animals, and a 48-h occlusive patch with 0.5 ml sodium PCA was applied the next day. Twenty days after the epidermal induction, the animals were challenged using a 24-h occlusive patch with 10% sodium PCA. Two challenge control groups (5 animals/dose) and a positive control group (10 animals exposed to 2,4-dinitrochlorobenzene) were used. No reactions were observed at challenge with sodium PCA.

The sensitization potential of the DL-form of sodium PCA also was examined in a GPMT.[10] A group of 10 female Hartley guinea pigs were treated in the same manner as described above, except the intradermal and epidermal inductions were with

25% test article; the epidermal challenge concentration was 10%. No skin reactions were reported, and the DL-form of sodium PCA was not a sensitizer in guinea pigs.

Human

In a clinical study of dermal irritation using open patch test methods on various sites of the body, 2 of 13 volunteers had reactions to 6.25% sodium PCA applied to their backs and 3 volunteers developed erythema when concentrations of 12.5% sodium PCA and greater were applied.[1] These reactions disappeared within 30 minutes. No reactions were observed when sodium PCA was applied to the skin of the forehead, cheek, or neck. A formulation containing 2.0% sodium PCA was negative in a mini-cumulative irritation test. In another study, no significant irritation was observed when 46 volunteers were treated with 30% sodium PCA using open patch test methods. Negative results were also obtained when 46 volunteers were tested-with concentrations up to 32% sodium PCA using occlusive patches. Provocative tests of 0.2% sodium PCA using occlusive patches were also negative.

Clinical studies using 39 subjects indicated that 32% aq. sodium PCA is not a sensitizer. A maximization test of a cosmetic formulation containing 2.0% sodium PCA was also negative.

Phototoxicity

No phototoxic effects were observed in guinea pigs treated topically with 1% aq. sodium PCA.[1] In a clinical study using 39 subjects, 32% aq. sodium PCA was not a photosensitizer.

Ocular Irritation

No ocular irritation was observed when 50% aq. solutions of sodium PCA was instilled into the conjunctival sac of the eye of rabbits.[1]

The ocular irritation potential of sodium PCA was evaluated *in vitro* using a chicken eye test method for identifying ocular corrosives and severe irritants; sodium PCA was classified as non-irritating.[10] Sodium PCA also was found to be non-irritating to rabbit eyes in an *in vivo* study. Sodium PCA, 0.1 g neat, was instilled into the conjunctival sac of one eye of three New Zealand White rabbits, and the eyes were rinsed after 1 h. Slight conjunctival redness and discharge were observed in all three animals 1 h after administration; all reactions were reversed within 48 h, and sodium PCA was considered non-irritating.

SUMMARY

In 1999, the Panel concluded that PCA and sodium PCA were safe as used in cosmetics, and that these ingredients should not be used in cosmetic products containing nitrosating agents. Three previously un-reviewed salts of PCA, i.e., calcium PCA, magnesium PCA, and potassium PCA, are being proposed for addition to this group. These five ingredients are reported to function as skin conditioning agents – humectant in cosmetic formulations.

VCRP data obtained from the FDA, and data received in response to surveys of the maximum reported use concentration by category that were conducted by the Council, indicate that PCA and the four PCA salts are all in use in cosmetic formulations. Sodium PCA has the most reported uses and the highest concentration of use; it is reported to be used in 1289 formulations, and the maximum leave-on and rinse-off concentrations of use are 2.5% in nail creams and lotions and 3% in skin cleansing preparations, respectively. The frequency of use of both PCA and sodium PCA has increased since the original safety assessment, but the concentration of use has not changed much; in the original safety assessment, the maximum use reported was 2.5% PCA and sodium PCA in a moisturizer.

Sodium PCA (tested as the L-form) was relatively non-toxic in several animal studies. The dermal and oral LD_{50}s in rats were >2 g/kg, which was the highest dose tested, and sodium PCA was not a developmental or reproductive toxicant in rats. In the oral (by gavage) reproductive and developmental toxicity study, the NOAEL was 1000 mg/kg bw/day, which again, was the highest dose tested.

Sodium PCA (L-form) was not was not genotoxic in an Ames test, mammalian cell gene mutation assay, or chromosomal aberration assay, with or without metabolic activation.

Sodium PCA was not a dermal or ocular irritant, nor was it a sensitizer. Dermally, undiluted sodium PCA was considered to be non-irritating in a reconstructed human epidermis model, and in ocular testing, sodium PCA was classified as non-irritating both *in vitro* and in rabbit eyes. Both the L- and DL-forms of sodium PCA were not sensitizers in guinea pigs. In a GPMT of the L-form, 20% aq. sodium PCA was used for both intradermal and epidermal induction, and 10% was used at challenge. With the DL-form, 25% aq. sodium PCA was used for both intradermal and epidermal induction, and again 10% was used at challenge.

Table 1. Definition, Structure, and Function

Ingredient (CAS No, if available)	Definition[2]	Structure[2]	Function(s)[2]
PCA (149-87-1, DL-; 98-79-3)	the cyclic organic compound that conforms to the formula *the γ-lactam dehydration product of glutamic acid.*		skin conditioning agent - humectant
Sodium PCA (54571-67-4, DL-; 28874-51-3, L-)	the sodium salt of PCA		skin conditioning agent – humectant; hair conditioning agent - humectant
Calcium PCA (31377-05-6)	the calcium salt of PCA		skin conditioning agent - humectant
Magnesium PCA (5819-47-6)	the magnesium salt of PCA		skin conditioning agent - humectant
Potassium PCA (4810-50-8)	the potassium salt of PCA		skin conditioning agent - humectant

Table 2. Current and historical frequency and concentration of use according to duration and exposure

	# of Uses		*Max Conc of Use (%)*		*# of Uses*		*Max Conc of Use (%)*	
	PCA				**Sodium PCA**			
	2014[4]	**1996[1]**	**2014[5]**	**1995[1] ****	**2014[4]**	**1996[1]**	**2014[5]**	**1995[1] ****
Totals*	**106**	**25**	**0.000012-1.9**	**0.05-2.5**	**1289**	**437**	**0.00005-3**	**0.001-2.5**
Duration of Use								
Leave-On	*84*	*14*	*0.000012-1.9*	*≤0.1-2.5*	*826*	*302*	*0.00005-2.5*	*0.1-2.5*
Rinse-Off	*22*	*11*	*0.001-0.0022*	*0.05-1.2*	*461*	*135*	*0.0023-3*	*0.001-1.2*
Diluted for (Bath) Use	*NR*	*NR*	*NR*	*NR*	*2*	*NR*	*0.00005-0.05*	*0.001 (as 50% conc)*
Exposure Type								
Eye Area	13	1	0.000012-0.87	NR	50	8	0.0001-2	NR
Incidental Ingestion	1	NR	0.0012	NR	3	1	0.0018	NR
Incidental Inhalation-Spray	1; 29[a]; 28[b]	6[a]; 2[b]	0.0012; aerosol: 0.0026-0.003; pump: 0.01	2.5[a]	34; 313[a]; 300[b]	25; 128[a]; 46[b]	0.0025; aerosol: 0.0002-0.052; pump: 0.05-0.2; 0.05[b]	0.001 (as 50% conc); ≤2.5[a]; 1.04[b]
Incidental Inhalation-Powder	28[b]	NR	0.000012-1.9; 0.0012-0.05[c]	NR	3; 300[b]; 2[c]	46[b]; 1[c]	0.05[b]; 0.00005-1[c]	1.04[b]
Dermal Contact	95	14	0.000012-1.9	0.05-2.5	1133	292	0.00005-3	≤2.5
Deodorant (underarm)	NR	NR	NR	NR	2[a]	NR	NR	NR
Hair - Non-Coloring	10	10	0.001-0.49	NR	147	144	0.0002-1.5	0.001-1 (as 50% conc)
Hair-Coloring	NR	1	NR	NR	NR	NR	NR	NR
Nail	NR	NR	NR	NR	7	NR	0.25-2.5	NR
Mucous Membrane	13	NR	0.0012	NR	261	8	0.00005-1	NR
Baby Products	NR	NR	NR	NR	5	1	NR	0.1

*Because each ingredient may be used in cosmetics with multiple exposure types, the sum of all exposure types may not equal the sum of total uses.

[a] Includes products that can be sprays, but it is not known whether the reported uses are sprays

[b] Not specified whether this product is a spray or a powder or neither, but it is possible it may be a spray or a powder, so this information is captured for both categories of incidental inhalation

[c] Includes products that can be powders, but it is not known whether the reported uses are powders

NR – no reported use

** - at the time of the original safety assessment, concentration of use data were not reported by the FDA; however, some data were proved by industry

Table 3. Current frequency and concentration of use according to duration and exposure

	# of Uses	*Max Conc of Use (%)*	*# of Uses*	*Max Conc of Use (%)*	*# of Uses*	*Max Conc of Use (%)*
	Calcium PCA		**Magnesium PCA**		**Potassium PCA**	
	2014[4]	**2014[5]**	**2014[4]**	**2014[5]**	**2014[4]**	**2014[5]**
Totals*	**15**	**0.01-0.2**	**57**	**0.1-0.18**	**10**	**0.005-0.75**
Duration of Use						
Leave-On	*15*	*0.01-0.2*	*37*	*0.1*	*4*	*0.005-0.75*
Rinse-Off	*NR*	*0.001*	*20*	*0.18*	*6*	*0.013-0.085*
Diluted for (Bath) Use	*NR*	*NR*	*NR*	*NR*	*NR*	*NR*
Exposure Type						
Eye Area	4	0.01-0.1	3	NR	1	0.5
Incidental Ingestion	NR	0.2	NR	NR	NR	NR
Incidental Inhalation-Spray	4[a]; 2[b]	NR	14[a]; 12[b]	NR	3[a]	NR
Incidental Inhalation-Powder	1; 2[b]	0.1; 0.1[c]	12[b]	0.1[c]	NR	0.05-0.75[c]
Dermal Contact	15	0.001-0.1	48	0.1-0.18	10	0.005-0.75
Deodorant (underarm)	NR	NR	2[a]	NR	NR	NR
Hair - Non-Coloring	NR	NR	9	NR	NR	NR
Hair-Coloring	NR	NR	NR	NR	NR	NR
Nail	NR	NR	NR	NR	NR	NR
Mucous Membrane	NR	0.2	2	NR	NR	NR
Baby Products	NR	NR	NR	NR	NR	NR

See Table 2 for explanation of footnotes

REFERENCES

1. Andersen FA (ed). Final safety assessment for PCA and sodium PCA. *Int J Toxicol*. 1999;18(Suppl 2):25-34.

2. Nikitakis J and Breslawec HP. International Cosmetic Ingredient Dictionary and Handbook. 15 *ed*. Washington, DC: Personal Care Products Council, 2014.

3. European Chemicals Agency (ECHA). Information on Chemicals. http://echa.europa.eu/information-on-chemicals. Date Accessed 7-11-2014.

4. Food and Drug Administration (FDA). Frequency of use of cosmetic ingredients. *FDA Database.* 2014.

5. Personal Care Products Council. 4-29-2014. Concentration of Use by FDA Product Category: PCA and its Salts. Unpublished data submitted by Personal Care Products Council.

6. Rothe H. Special Aspects of Cosmetic Spray Evalulation. 9-26-2011. Unpublished data presented at the 26 September CIR Expert Panel meeting. Washington, D.C.

7. Johnsen MA. The influence of particle size. *Spray Technol Marketing*. 2004;14(11):24-27.

8. Rothe H, Fautz R, Gerber E, Neumann L, Rettinger K, Schuh W, and Gronewold C. Special aspects of cosmetic spray safety evaluations: Principles on inhalation risk assessment. *Toxicol Lett*. 2011;205(2):97-104.

9. Bremmer HJ, Prud'homme de Lodder LCH, and Engelen JGM. Cosmetics Fact Sheet: To assess the risks for the consumer; Updated version for ConsExpo 4. 2006. Report No. RIVM 320104001/2006. pp. 1-77.

10. European Chemicals Agency (ECHA. Sodium 5-oxo-L-prolinate (sodium PCA; CAS No. 28874-51-3). http://apps.echa.europa.eu/registered/data/dossiers/DISS-e18edfe9-02a1-58ce-e044-00144f67d031/DISS-e18edfe9-02a1-58ce-e044-00144f67d031_DISS-e18edfe9-02a1-58ce-e044-00144f67d031.html. Date Accessed 7-14-2014.

PCA	03C - Eye Shadow	6
PCA	03D - Eye Lotion	2
PCA	03G - Other Eye Makeup Preparations	5
PCA	05A - Hair Conditioner	4
PCA	05B - Hair Spray (aerosol fixatives)	1
PCA	05F - Shampoos (non-coloring)	3
PCA	05G - Tonics, Dressings, and Other Hair Grooming Aids	2
PCA	07A - Blushers (all types)	2
PCA	07B - Face Powders	5
PCA	07C - Foundations	2
PCA	07E - Lipstick	1
PCA	07I - Other Makeup Preparations	3
PCA	10A - Bath Soaps and Detergents	11
PCA	10E - Other Personal Cleanliness Products	1
PCA	12A - Cleansing	1
PCA	12C - Face and Neck (exc shave)	25
PCA	12D - Body and Hand (exc shave)	3
PCA	12F - Moisturizing	19
PCA	12G - Night	7
PCA	12H - Paste Masks (mud packs)	2
PCA	12I - Skin Fresheners	1

SODIUM PCA	01B - Baby Lotions, Oils, Powders, and Creams	2
SODIUM PCA	01C - Other Baby Products	3
SODIUM PCA	02B - Bubble Baths	2
SODIUM PCA	03B - Eyeliner	1
SODIUM PCA	03D - Eye Lotion	24
SODIUM PCA	03E - Eye Makeup Remover	5
SODIUM PCA	03F - Mascara	2
SODIUM PCA	03G - Other Eye Makeup Preparations	18
SODIUM PCA	04A - Cologne and Toilet waters	1
SODIUM PCA	04E - Other Fragrance Preparation	14
SODIUM PCA	05A - Hair Conditioner	55
SODIUM PCA	05B - Hair Spray (aerosol fixatives)	19
SODIUM PCA	05C - Hair Straighteners	1
SODIUM PCA	05E - Rinses (non-coloring)	2
SODIUM PCA	05F - Shampoos (non-coloring)	32
SODIUM PCA	05G - Tonics, Dressings, and Other Hair Grooming Aids	23
SODIUM PCA	05H - Wave Sets	2
SODIUM PCA	05I - Other Hair Preparations	13
SODIUM PCA	07A - Blushers (all types)	1
SODIUM PCA	07B - Face Powders	3
SODIUM PCA	07C - Foundations	16
SODIUM PCA	07E - Lipstick	3
SODIUM PCA	07I - Other Makeup Preparations	8
SODIUM PCA	08B - Cuticle Softeners	2
SODIUM PCA	08C - Nail Creams and Lotions	2
SODIUM PCA	08G - Other Manicuring Preparations	3
SODIUM PCA	10A - Bath Soaps and Detergents	192
SODIUM PCA	10B - Deodorants (underarm)	2
SODIUM PCA	10E - Other Personal Cleanliness Products	64
SODIUM PCA	11A - Aftershave Lotion	19
SODIUM PCA	11E - Shaving Cream	8
SODIUM PCA	11F - Shaving Soap	2
SODIUM PCA	11G - Other Shaving Preparation Products	4
SODIUM PCA	12A - Cleansing	75
SODIUM PCA	12C - Face and Neck (exc shave)	130
SODIUM PCA	12D - Body and Hand (exc shave)	169

SODIUM PCA	12E - Foot Powders and Sprays	1
SODIUM PCA	12F - Moisturizing	217
SODIUM PCA	12G - Night	35
SODIUM PCA	12H - Paste Masks (mud packs)	19
SODIUM PCA	12I - Skin Fresheners	24
SODIUM PCA	12J - Other Skin Care Preps	57
SODIUM PCA	13A - Suntan Gels, Creams, and Liquids	3
SODIUM PCA	13B - Indoor Tanning Preparations	8
SODIUM PCA	13C - Other Suntan Preparations	3

CALCIUM PCA	03B - Eyeliner	1
CALCIUM PCA	03C - Eye Shadow	2
CALCIUM PCA	03G - Other Eye Makeup Preparations	1
CALCIUM PCA	07A - Blushers (all types)	1
CALCIUM PCA	07B - Face Powders	1
CALCIUM PCA	07C - Foundations	3
CALCIUM PCA	12C - Face and Neck (exc shave)	2
CALCIUM PCA	12F - Moisturizing	2
CALCIUM PCA	12G - Night	2

MAGNESIUM PCA	03D - Eye Lotion	2
MAGNESIUM PCA	03E - Eye Makeup Remover	1
MAGNESIUM PCA	05A - Hair Conditioner	5
MAGNESIUM PCA	05I - Other Hair Preparations	4
MAGNESIUM PCA	07I - Other Makeup Preparations	1
MAGNESIUM PCA	10A - Bath Soaps and Detergents	1
MAGNESIUM PCA	10B - Deodorants (underarm)	2
MAGNESIUM PCA	10E - Other Personal Cleanliness Products	1
MAGNESIUM PCA	11A - Aftershave Lotion	2
MAGNESIUM PCA	11G - Other Shaving Preparation Products	1
MAGNESIUM PCA	12A - Cleansing	9
MAGNESIUM PCA	12C - Face and Neck (exc shave)	9
MAGNESIUM PCA	12D - Body and Hand (exc shave)	3
MAGNESIUM PCA	12F - Moisturizing	7
MAGNESIUM PCA	12G - Night	4
MAGNESIUM PCA	12H - Paste Masks (mud packs)	2
MAGNESIUM PCA	12J - Other Skin Care Preps	3

POTASSIUM PCA	03G - Other Eye Makeup Preparations	1
POTASSIUM PCA	12A - Cleansing	6
POTASSIUM PCA	12F - Moisturizing	3

Final Safety Assessment for PCA and Sodium PCA[1]

PCA is the cosmetic ingredient term used for the cyclic organic compound known commonly as pyroglutamic acid. Sodium PCA is the sodium salt of PCA. Both are used as hair and skin conditioning agents. These ingredients are recommended to be used in a concentration range of 0.2–4%. One optical isomer of PCA (the L form) is a naturally occurring component of mammalian tissue. PCA applied to the skin is absorbed to a limited extent. Absorption is in addition to PCA already present in the skin. In short-term and subchronic studies in several animal species, findings were unremarkable except for neurotoxicity in mice when injected interstriatally. No such findings were seen in similar studies using rats or with oral administration using mice. In animal studies, Sodium PCA was nonirritating to the eye and skin at concentrations up to 50%. No evidence of phototoxicity, sensitization, or comedogenicity was found. These ingredients were not genotoxic. In a range of clinical tests, PCA and Sodium PCA were found to be nonirritating and nonsensitizing (with and without UV exposure). Based on the low actual skin penetration of dermally applied PCA and in recognition of the endogenous levels found in the skin, it was considered that reproductive and developmental toxicity data were not critical to completion of the safety assessment. Based on the available data, it was concluded that PCA and Sodium PCA are safe as presently used in cosmetic formulations. These ingredients, however, should not be used in cosmetic products containing nitrosating agents.

PCA is a cyclic organic compound, more commonly known as pyroglutamic acid; Sodium PCA is the sodium salt of PCA. Both compounds are used as hair and skin conditioning agents in cosmetic formulations. This report reviews the available safety data on these ingredients.

CHEMISTRY

Definition and Structure

PCA (CAS No. 98-79-3) is the cyclic organic compound that conforms to the formula shown in Figure 1 (Wenninger and McEwen 1997). It is an internal amide of L-glutamic acid found in vegetables, fruits, grasses, and molasses (Budavari 1989). Other technical names for this ingredient include: 5-Oxo-L-Proline; L-Proline, 5-Oxo-; L-Pyroglutamic Acid; 2-Pyrrolidone-5-Carboxylic Acid (Wenninger and McEwen 1997); 5-Oxo-2-Pyrrolidinecarboxylic Acid; Glutimic Acid; Glutiminic Acid; α-Aminoglutaric Acid Lactam; and Glutamic Acid Lactam (Budavari 1989). Trade names for PCA are Ajidew A-100 and Pidolidone, and trade names of mixtures containing PCA are Ajidew SP-100 and Hydro-Diffuser Microreservoir (Wenninger and McEwen 1997).

Sodium PCA (CAS No. 28874-51-3) is the sodium salt of PCA (q.v.) that conforms to the formula shown in Figure 1 (Wenninger and McEwen 1997). Other technical names for this ingredient are: 5-Oxo-DL-Proline, Monosodium Salt; PCA Soda; DL-Proline, 5-Oxo-, Monosodium Salt; Sodium Pyroglutamate; and Sodium DL-2-Pyrrolidone-5-Carboxylate. Trade names for Sodium PCA include: Ajidew N-50, Dermidrol, and Nalidone. This ingredient is also found in mixtures with the following trade names: Ajidew SP-100, Aquaderm, Endomine NMF, Hydrolyzed NMF, Lactil, Moisturizing Liposomes, Phyto NMF, Prodew 100, Prodew 200, Prodew 300, and Ritaderm (Wenninger and McEwen 1997).

Chemical and Physical Properties

PCA is an orthorhombic bisphenoidal crystal with a molecular weight of 129.11. The melting point of PCA is 162–163°C and it is soluble in water, alcohol, and acetone (Budavari 1989). PCA is nonhygroscopic, but its sodium salt is extremely hygroscopic (Ajinomoto 1994a). The ultraviolet (UV) absorption spectrum of PCA indicates very weak absorption from 320–240 nm and strong absorption from 240 nm to shorter wavelength (Lin, Shieh, and Tung 1971).

Method of Manufacture

PCA is prepared from L-glutamic acid by autoclaving with an equal weight of water at 135–140°C (Budavari 1989).

Impurities

No by-products are reported in the production of PCA and Sodium PCA from glutamic acid and sodium glutamate, respectively (Ajinomoto USA, Inc. 1995). It could be expected that some dimer or polymer of glutamic acid would be found, but none was detected with carnet analytical methods. However, glutamic acid and sodium glutamate are possible impurities.

Analytical Methods

Analytical methods for determining and/or isolating PCA include: capillary isotachophoresis (Stehle and Fürst 1987); high-performance liquid chromatography (Shih 1985); reverse phase high-performance liquid chromatography (Bousquet et al. 1983);

Received 25 February 1999; accepted 12 May 1999.

[1]Reviewed by the Cosmetic Ingredient Review Expert Panel. Susan N. J. Pang, former Scientific Analyst and Writer, prepared this report. Address correspondence to Dr. F. Alan Andersen, Director, CIR, 1101 17th Street, NW, Suite 310, Washington, DC 20036, USA.

International Journal of Toxicology, 18(Suppl. 2):25–34, 1999

1091-5818/99 $12.00 + .00



PCA



Sodium PCA

FIGURE 1
Chemical formulas for PCA and Sodium PCA (Wenninger and McEwen 1997).

enantiomeric separation (Zukowski, Pawlowska, and Armstrong 1992); and mass and gas spectrometry (Tham, Nyström, and Holmstedt 1968).

Nitrosation

Yamada, Yamamoto, and Tanimura (1981) investigated the nitrosation of PCA under conditions simulating those in the stomach following a meal. PCA was reacted with sodium nitrite at pH 2.5 and 37°C, and sulfamic acid was added to the mixture. The initial rate of reaction was very slow and the rate constant was 1.23×10^{-3} M^{-1} min^{-1}. The investigators noted that this rate value was 1.7% of that observed with hydanoic acid and 0.03% of that of nitrosomethylurea formation.

COSMETIC USE

PCA and Sodium PCA are used as a skin and hair conditioning agents (humectants) in cosmetic formulations (Wenninger and McEwen 1997). The product formulation data submitted to the Food and Drug Administration (FDA) in 1996 reported that PCA was used in a total of 25 cosmetic formulations and that Sodium PCA was used in a total of 437 products (Table 1) (FDA 1996).

One supplier of PCA and Sodium PCA recommends that these ingredients be used in a concentration range of 0.2–4%, and that the use concentration be <5% because of the possibility of inducing a reddening of the skin at that concentration (similar to alcohol blush) (Ajinomoto USA, Inc. 1995). Because concentration of use values are no longer reported to the FDA by the cosmetic industry (FDA 1992), the supplier has no way of knowing at what concentration its customers are using PCA and Sodium PCA; however, they suspect it is in the range of 0.1–4%. Data have been submitted to the Cosmetic Ingredient Review (CIR) by the Cosmetic, Toiletry, and Fragrance Association (CTFA) that give some use concentrations (CTFA 1995). These data are summarized in Table 2.

In 1984, product formulation data submitted to the FDA stated that PCA was used at concentrations up to 1% and that Sodium PCA was used at up to 10% (FDA 1984).

International

PCA and Sodium PCA are listed in the *Comprehensive Licensing Standards of Cosmetics by Category (CLS)* and must conform to the standards of the *Japanese Standards of Cosmetic Ingredients* (Yakuji Nippo, Ltd. 1994). They can be used in all *CLS* categories without restriction.

BIOLOGICAL PROPERTIES

Natural Occurrence

PCA is a naturally occurring component of mammalian tissue. Tabachnick and LaBadie (1970) reported that 270 μmol/g wet weight was found using ion exchange chromatography in epidermal scrapings taken from albino guinea pigs. In further studies with epidermal samples from guinea pigs, humans, dogs, rats, and mice, the total amount of free PCA was 186.0, 44.9, 30.9, 21.3, and 19.0 μmol/g wet weight, respectively. Optical rotatory dispersion studies of PCA isolated from guinea pig skin indicated that the epidermal PCA was the L isomer (Wolfersberger et al. 1973).

The concentration of PCA in other tissues of guinea pigs was much lower than that found in the epidermis. Wolfersberger et al. (1973) examined the liver, spleen, pancreas, kidneys, intestine, brain, and blood cells of guinea pigs and found that the highest concentration of PCA was in the brain (4.06 μmol/g wet weight). PCA content was much lower in the other tissues. Whole blood and plasma had concentrations of 53.1 and 31.2 μmol/100 ml, respectively.

L-PCA is also present in the human epidermis at approximately 16.5 mg/g fresh tissue (Marstein, Jellum, and Eldjarn 1973) and in normal human plasma at approximately 21.6 μmol/100 ml plasma (Wolfersberger and Tabachnick 1973). Free PCA is also found in the cerebrospinal fluid as the L-isomer and in the urine as both the L- and D-isomers (Wilk and Orlowski 1973).

PCA (and Sodium Lactate) constitute the most hygroscopic fraction of the stratum corneum (Middleton 1978).

Biosynthesis

The major pathway by which L-PCA is formed involves the catalysis of γ-glutamyl amino acids by γ-glutamyl cyclotransferase (van der Werf and Meister 1975).

TABLE 1
Cosmetic product formulation data on PCA and SodiumPCA (FDA 1996)

Product category	Total no. formulations in category	Total no. containing ingredient
PCA		
Other eye makeup preparations	136	1
Hair conditioners	715	8
Permanent waves	434	2
Other hair coloring preparations	71	1
Blushers (all types)	277	2
Cleansing	820	1
Face and neck (excluding shaving)	300	2
Moisturizing	942	5
Night	226	1
Paste masks (mud packs)	300	1
Other skin care preparations	810	1
1996 total		**25**
Sodium PCA		
Baby lotions, oils, powders, and creams	64	1
Eyeliner	533	1
Eye lotion	22	2
Eye makeup remover	95	1
Other eye makeup preparations	136	4
Other fragrance preparations	195	1
Hair conditioners	715	31
Hair sprays (aerosol fixatives)	334	24
Permanent waves	434	14
Rinses (noncoloring)	60	2
Shampoos (noncoloring)	972	30
Sodium PCA (cont.)		
Tonics, dressings, and other hair grooming aids	604	13
Wave sets	95	1
Other hair preparations	395	29
Blushers (all types)	277	2
Foundations	355	2
Lipstick	997	1
Other makeup preparations	157	1
Bath soaps and detergents	372	5
Douches	19	1
Other personal cleanliness products	339	1
Aftershave lotion	268	6
Beard softeners	4	1
Cleansing	820	23
Face and neck (excluding shaving)	300	11
Body and hand (excluding shaving)	1012	35
Moisturizing	942	74
Night	226	11
Paste masks (mud packs)	300	11
Skin fresheners	244	16
Other skin care preparations	810	31
Suntan gels, creams, and liquids	196	8
Indoor tanning preparations	67	3
Other suntan preparations	68	3
Listing under trade names		11
Listing under mixture trade names		26
1996 total		**437**

Enzymatic synthesis in situ was considered the mechanism responsible for the high concentration of PCA in the guinea pig epidermis. The specific activities of PCA-forming enzymes was determined using homogenates of epidermis. The specific activities for γ-glutamyl cyclotransferase, glutamine cyclotransferase, glutamic acid cyclotransferase, and pyrrolidone carboxyl peptidase were 3.05, 0.99, 0.58, and 0.03 μmol/h/mg protein, respectively. It was concluded that if the specific activities of the three cyclotransferases reflect their activity in situ, any of the three could account for the formation of the high concentration of PCA in the epidermis (Wolfersberger and Tabachnick 1974).

In another study, DeLapp and Dieckman (1977) investigated the biosynthesis of PCA in the epidermis of the hairless mouse by administrating a single subcutaneous injection of [^{3}H]-glutamic acid to HRS/J mice and observing the specific activity of PCA in the skin. The specific activity of PCA increased slowly in the epidermis and reached a peak 3–4 days after injection. Ninety-seven percent of the PCA content of the skin was in the stratum corneum. The investigators noted that topical application of cycloheximide inhibited the incorporation of [^{3}H]-glutamic acid into the epidermal PCA. This inhibitory effect was greater prior to injection of [^{3}H]-glutamic acid than after injection. The researchers concluded that protein synthesis was involved in the formation of PCA from glutamic acid rather than a direct conversion of the amino acid. The high concentration of PCA in the epidermis is probably due to its accumulation in the stratum corneum and its relatively slow rate of turnover in comparison to other tissues.

Absorption, Distribution, Metabolism, and Excretion

The in vitro percutaneous absorption of 5, 10, and 20% *w/v* [^{14}C]-Sodium PCA was determined using fresh dermatomed human cadaver thigh skin (Surge Laboratory, 1995). The amount of radioactivity recovered in the receptor fluid over 24 hours was 1.23, 1.67, and 1.08% for applied doses of 5, 10, and 20% Sodium PCA, respectively. The amount recovered in the

TABLE 2
Concentration of use data for PCA and Sodium PCA (CTFA 1995)

Product in which used	Concentration
PCA	
Skin care preparations	<0.1%
PCA and Sodium PCA	
Liquid soap	0.05%
Moisturizer	2.5%
Cleanser	1.2%
Facial mask	1%
Sodium PCA	
Body lotions	0.1%
Foundations	2%
Other makeup preparations	0.225%
Bath soaps and detergents	0.001%
Cleansing (cold creams, etc.)	1%
Face and neck product	1.04%
Moisturizing skin care preparations	1%
Night skin care preparations	2%
Paste masks (mud packs)	0.05%
Other skin care preparations	1%
Sodium PCA 50%	
Other bath preparations	0.001%
Hair conditioner	1%
Hair spray	0.001%
Shampoos	0.50–1%
Tonics, dressings, and other hair grooming aids	0.5%
Other hair preparations	0.001%

epidermis was 2.47, 2.48, and 2.05% and in the dermis was 2.27, 2.63, and 2.76% with 5, 10, and 20% Sodium PCA, respectively. Because receptor fluid accumulations increased with time and the greater receptor fluid accumulations were at the latter part of the study, it was assumed that absorption was an ongoing process at 24 hours and therefore the skin content should be considered part of the absorption process. Accordingly, the percutaneous absorption of 5, 10, and 20% Sodium PCA through human skin was 5.97, 6.78, and 5.89%, respectively. The calculated flux for 5, 10, and 20% [^{14}C]Sodium PCA was 12.9, 29.1, and 50.4 μg/cm^2/h; flux increased almost linearly with dose.

Chanal et al. (1988) investigated the penetration of Sodium PCA into the brain and plasma of Wistar rats. Seven male rats were given orally 500 mg/kg [^{3}H]-Sodium PCA (20 μCi/rat) and one rat was killed for blood and brain analyses at 15, 30, 60, 90, 120, 240, and 480 minutes following administration. A 30-fold increase in the plasma concentration of [^{3}H]-PCA was observed and maximum values were achieved between 90 and 120 min. Brain concentrations increased by 100% after 120 minutes. Over 60% of the cerebral radioactivity was identified as [^{3}H]-PCA, which remained unchanged for at least 2–4 hours.

A fasted rabbit was fed 300 μl ^{14}C-PCA (20 μCi of activity) in a 3-g carrier solution of PCA. Blood samples were taken by cardiac puncture at 0.5, 1, 2, 3, 4, 6, 18, and 24 hours for determination of serum concentrations of radioactivity and for identification of certain amino acids. Radioactivity was identified in the serum as 42% glutamic acid, 42% γ-aminobutyric acid, and 16% PCA. The absorption rate was not determined (Lange and Carey 1966).

The metabolism of PCA was also investigated in mice. Three mice were given orally 1 ml of a PCA carrier solution containing 1 μCi ^{14}C-PCA. After 3 hours, the mice were killed and the blood, brain, and kidneys were pooled for radioactivity evaluation. Radioactivity was found in the serum as PCA, in the brain as glutamic acid, and in the kidneys as γ-aminobutyric acid. The absorption rate was not determined (Lange and Carey 1966).

Greenberg and Schmidt (1936) reported that oral administration of PCA to dogs resulted in approximately 70% of the administered dose being absorbed. Thirty percent of the absorbed dose was excreted unchanged in the urine and the remainder was converted to urea. Consistent with these findings, Pederson and Lewis (1944) reported that when PCA was administered via stomach tube to rabbits, some of the administered PCA nitrogen was excreted as urinary urea nitrogen.

In a study with bile fistula rats, bile was not a major route for the excretion of PCA when given either orally or subcutaneously (Greenberg and Schmidt 1936).

Ramakrishna, Krishnaswamy, and Rajagopal (1970) injected a male albino rat intraperitoneally with [U-^{14}C]PCA (134 μCi; specific radioactivity 55 mCi/mmol). The rat was housed in a metabolic cage for 8 hours, and the distribution of radioactivity in the excretory products and tissues was determined. A total of 64% of the administered radioactivity was recovered from the various fractions. Approximately 87% of the radioactivity was found in expired CO_2, of which 80% was exhaled within the 1st hour. Radioactivity was also found in fractions of various tissues, but at much lower concentrations.

Additionally, the investigators used isolated slices of the liver, kidneys, and brain incubated with radioactive PCA to determine whether different tissues could metabolize PCA. They found 4–5% of the total radioactivity in the free amino acid pool of the liver and kidneys, 50% of which was identified as glutamic acid. Additional studies indicated that metabolism of PCA by these tissues could be inhibited with electron transport inhibitors. No oxidation of PCA by the tissues of the brain was observed.

In another study, groups of two to three NCS mice were injected subcutaneously (s.c.) with 2 μmol to 2 mmol [U-^{14}C]PCA (1.2×10^6 cpm of ^{14}C). The mice were housed in separate metabolic cages and $^{14}CO_2$ was collected for up to 6 hours. At concentrations up to 80 μmol, the percent recovery of $^{14}CO_2$ was 58–70% of the dose after 3 hours and 65–72% after 6 hours. However, at the two higher concentrations tested, 0.2 and 2 mmol, the recovery of $^{14}CO_2$ was much lower. The investigators noted that a relatively large amount of PCA was metabolized during this period. After a dose of 2 mmol PCA, approximately

240 μmol of PCA was metabolized within 6 hours. It was concluded that the mouse has a substantial capacity for utilization of 5-oxoprolinase (Hsu and Meister 1985).

These researchers then investigated the effects of 5-oxoprolinase inhibitors on $^{14}CO_2$ formation. Mice were injected s.c. with one of three inhibitors, L-2-imidazolidone-4-carboxylate, L-2-oxothiazolidine-4-carboxylate, and 3-methyl-5-oxoproline, followed by 10 μmol PCA (1.2×10^6 cpm) 10 minutes later. As a control, the effects of these inhibitors on the metabolism of glutamate were also determined. The three inhibitors significantly reduced the rate of $^{14}CO_2$ formation from [U-^{14}C]PCA, but had little effect on the rate of $^{14}CO_2$ formation from [U-^{14}C]glutamate (Hsu and Meister 1985).

ANIMAL TOXICOLOGY

Acute Oral Toxicity

The oral LD_{50} of Sodium PCA was 10.4 g/kg for male mice (Ajinomoto Co., Inc. 1994c). In another study, the LD_{50} for 50% Sodium PCA was >2.0 g/kg for rats (Centre International de Toxicologie 1990).

Short-Term Oral Toxicity

Five male and five female Sprague-Dawley rats were fed 1.5% PCA in their diet for 12 days and body weight gain was monitored. A control group of rats was fed untreated feed. No significant effect on growth was observed (Lin, Shieh, and Tung 1971).

Subchronic Oral Toxicity

The effect of PCA on body weight gain was studied using Sprague-Dawley rats. Six male rats were fed 1% PCA in their diet for 70 days and a control group of six rats was fed untreated feed. No significant effect on growth was observed during the first 10 days of the experiment. However, at the end of the study, the net gain in body weight was 238.4 g for the rats fed 1% PCA and 214.4 g for the controls. The investigators concluded that the difference between these two groups was of borderline significance (Lin, Shieh, and Tung 1971).

In another study, male and female rats were fed diets containing 2, 4, or 8% Sodium PCA for 13 and 26 weeks. A separate group of rats was fed a diet containing sodium propionate to serve as a sodium ion control. No adverse effects were observed in hematologic parameters, blood chemistry, urinalysis, macroscopic appearance or microscopic findings of the major organs. Diarrhea or softened feces was observed in the high dose group as well as in the control group for up to 9 weeks, by which time the intestinal tract probably adapted to the dietary treatment. The kidneys of these rats were also enlarged, an indication that renal function could have physiologically adapted to compensate for the prolonged sodium ion loading (Ishii et al. 1992).

Neurotoxicity

Caccia et al. (1983) investigated the kinetics and neurotoxicity of PCA using CD-1 (ICR) mice. In the kinetic study, groups of adult male mice and 10-day old male and female mice were given orally 0.5 g/kg PCA. The mice were killed at different time intervals ranging from 5–480 minutes after administration, and blood samples and brains were collected for analysis. In adults, the concentration of PCA in the plasma increased by a factor of 55.8 at 30 minutes, whereas the concentration in the brain reached a maximum by a factor of 4.5 at 60 minutes. A 1.3-fold increase was observed in the concentration of glutamic acid in the plasma, but no changes in concentration were observed in the brain. In 10-day-old mice, PCA increased 69-fold in the plasma and 5.7-fold in the brain at 30 minutes after dosing. In the neurotoxicity study, groups of 12 10-day-old mice were given 2 and 4 g/kg 10% aqueous PCA by gastric intubation. Six hours after administration the mice were killed and the brains were removed. Control mice that were not treated with PCA were also examined. The number of necrotic neurons in the arcuate nuclei was not significantly different between the experimental and control group of mice.

PCA has also been studied for neurotoxicity using the intrastriatal route of administration. In behavioral and neurology studies with mice, Rieke, Scarfe, and Hunter (1984) observed dose-related changes in behavior and dose-dependent increases in the number of lesion of the neuropil following 1-μl injections of 0.02–100 μmol PCA. However, no neurotoxicity was observed in a study of rats stereotaxically injected in the striatum with 250 nM PCA (McGeer and Singh 1984).

Dermal Irritation

The primary skin irritation potential of 2, 4, 8, 16, 32, and 50% aqueous Sodium PCA was tested using groups of 10 white female Hartley guinea pigs. Sodium PCA was applied to the shaved trunk of each animal once a day for 14 days. Observations were made every day and for an additional 2 weeks following the last application. Distilled water was used as the control. No irritation was observed at any of the concentrations tested (Ajinomoto Co., Inc. 1994b).

In another study, 5% aqueous Sodium PCA was applied to the abraded skin of 30 white female Hartley guinea pigs. Applications were made once a day for 3 days. A control group of guinea pigs was treated similarly with distilled water. Sodium PCA was nonirritating to the skin (Ajinomoto Co., Inc. 1994b).

Sodium PCA (50% aq.) was also tested for primary skin irritation using rabbits. Applications were made to both intact and abraded sites for 24 hours, and the sites were scored 24 and 72 hours after application. Sodium PCA was classified as a nonirritant (Usines Chimiques d'Ivry-la-Bataille [UCIB] 1989).

Sensitization

The 10 guinea pigs used in the primary skin irritation study (described earlier) were also used in a sensitization study. Two

weeks after being treated with 2, 4, 8, 16, 32, and 50% aqueous Sodium PCA for 14 consecutive days, 5% aqueous Sodium PCA was applied to the right mammary region of each guinea pig. These sites were scored after 48 and 72 hours. No signs of sensitization were observed (Ajinomoto Co., Inc. 1994b).

Phototoxicity

In a phototoxicity study, 1% aqueous Sodium PCA was applied to the shaved backs of 10 female white Hartley guinea pigs on days 1, 4, and 7. Each of the guinea pigs was irradiated with UV light (wavelengths not reported) for 10 minutes a day from days 1 to 10. The sites of application were scored on days 4 and 10. No evidence of phototoxicity was observed (Ajinomoto Co., Inc. 1994b).

Comedogenicity

A 50% solution of Sodium PCA (0.1 ml) was applied to the right ears of six male New Zealand albino rabbits 5 days a week for 2 weeks. The left ears were left untreated and served as controls. The rabbits were killed 6–8 hours after the last application and the epithelial tissue of the ears was removed for examination. No significant difference in the number of pilosebaceous units was found between the treated and control epithelial samples (UCIB 1987).

Ocular Irritation

A Draize test of 50% aqueous Sodium PCA was conducted using six male white rabbits. The right conjunctival sac of each rabbit was instilled with 0.1 ml 50% aqueous Sodium PCA. The eyes of three rabbits were rinsed 2–4 seconds after instillation, while the eyes of the remaining rabbits were left unrinsed. A control group of rabbits was treated with 0.9% NaCl. Each of the eyes was scored after 24, 48, 72, 96, and 168 hours. Very slight inflammation was observed in one rabbit of both the treated and control groups, but these signs subsided by the 72- or 96-hour readings (Ajinomoto Co., Inc. 1994b).

In a similar study, a 50% solution of Sodium PCA was also classified as nonirritating. Mild conjunctivitis was observed during the first hour following instillation but cleared by the 24-hour reading (UCIB 1990).

Mutagenicity

A *Salmonella* mutagenicity assay was performed with 780–25,000 μg/ml PCA and Sodium PCA using *Salmonella typhimurium* TA100 and TA98 with and without metabolic activation (Ajinomoto Co., Inc. 1992). PCA and Sodium PCA were not mutagenic.

The ability of PCA to induce chromosome damage was studied in vitro using cultured human peripheral lymphocytes (Huntingdon Life Sciences 1996). The vehicle, sterile water, was used as a negative control and chlorambucil and cyclophosphamide were used as the positive controls without and with metabolic activation, respectively. A preliminary toxicity test with 20- and 44-hour sampling times was first performed using doses of 80.625, 161.25, 322.5, 645, and 1290 μg/ml PCA without and with metabolic activation; the highest concentration tested was 10 mM. The first cytogenetic test used concentrations of 322.5, 645, and 1290 μg/ml PCA for the 20-hour sampling time with and without metabolic activation and for the 44-hour sampling time without metabolic activation. For the 44-hour sampling time with metabolic activation, concentrations of 322.5, 645, 860, 1075, and 1290 μg/ml were used. In the second cytogenetic test, which had only a 20-hour sampling time, concentrations of 322.5, 645, and 1290 μg/ml were used with and without metabolic activation.

In the first cytogenetic test, reductions in mean mitotic indices of 18 and 25% were observed with 322.5 and 645 μg/ml PCA, respectively, with metabolic activation and a 26% reduction was observed with 1290 μg/ml without metabolic activation at the 20-hour sampling time. Without and with metabolic activation, PCA did not result in biologically or statistically significant increases in the frequency of metaphases with aberrant chromosomes. In the second test, 1290 μg/ml PCA without metabolic activation produced a reduction in the mean mitotic index of 24%. This dose without metabolic activation also resulted in a small but statistically significant increase in the number of cells with aberrant chromosomes, including gaps. However, the investigators did not consider this of biological significance. No marked toxicity was apparent in either test. The number of cells with polyploidy was within the normal range in both tests. The investigators concluded that "PCA, under the conditions of test, did not show any evidence of clastogenic activity."

CLINICAL STUDIES

Dermal Irritation

Immediate contact reactions to Sodium PCA were investigated by Larmi, Lahti, and Hannuksela (1989). A dose of 10 μl of 6.25, 12.5, 25, and 50% Sodium PCA in distilled water was applied using open patch test methods to the forehead, cheek, neck, and upper back (1 × 1 cm area) of 13 male volunteers. The sites were examined at 5-minute intervals for up to 40 minutes and cutaneous blood flow at the test sites and control sites was measured with a laser-Doppler flowmetry (LDF) device. Three of the subjects developed erythema on their upper backs with concentrations of 12.5% Sodium PCA and greater and two subjects reacted to 6.25%. Irritant reactions observed within the first 5 minutes disappeared by 30 minutes. No irritancy was observed on the skin of the forehead, cheek, or neck, and no significant changes in LDF measurements were observed between the different test areas.

A skin fatigue test of 30% Sodium PCA using open patch test methods was performed using 46 male volunteers. Sodium PCA was applied to the upper left arm of each subject once a day for 14 days, and irritancy was scored on days 6 and 14. Water was used as the control agent. No signs of irritation were observed throughout the test period (Ajinomoto Co., Inc. 1972).

In another study, 4, 8, 16, and 32% aqueous Sodium PCA was applied under occlusive patches to the left side of the backs of 46 male volunteers for 24 hours. The sites were scored 3 hours after patch removal. Negative control sites were treated with distilled water, 5% polyethylene glycol, and 5% glycerine; one site was untreated. Overall, the average irritation scores were not significantly different between the different concentration groups or between those of the test and control groups. One of the subjects had diffuse erythema from all of the concentrations tested, and another had this type of reaction to 4 and 8% Sodium PCA but only partial erythema when tested with 16 and 32% Sodium PCA. It was noted that reactions of equal or lesser intensity were observed at the control sites of these individuals, even the site that received no applications (Ajinomoto Co., Inc. 1972).

A primary irritancy test of 0.2% Sodium PCA was also conducted using patients with eczematous dermatitis. Sodium PCA was applied under occlusive patches for 48 hours to two sites on the backs of 47 patients. Water was applied in a similar fashion and served as the control. The sites of application were scored 24 and 48 hours after patch removal. No significant evidence of irritation was observed (Ajinomoto Co., Inc. 1972).

A formulation containing 2.0% Sodium PCA was negative in a 4-day mini-cumulative irritancy test using occlusive patches and 18 volunteers (CTFA 1990).

Sensitization and Photosensitization

A maximization test with a formulation containing 2.0% Sodium PCA was conducted using 25 volunteers. Sodium lauryl sulfate (1.0% aqueous) was applied to the upper outer arm of each subject using an occlusive patch. After 24 hours, the patch was removed and 0.1 g of the formulation was applied to the same site under occlusive patches for 48 hours during the week and 72 hours during the weekend. This procedure was repeated for a total of five induction exposures. After a 10-day nontreatment period, the subjects were challenged on the opposite arm with 0.1 ml of a 10.0% aqueous solution of sodium lauryl sulfate for 1 hour, followed by application of the formulation using occlusive patches for 48 hours. Sites were scored 1 hour after patch removal and 24 hours later. No irritation was observed during the induction phase of the study, and no evidence of sensitization was observed (Ivy Laboratories 1991).

In the dermal irritancy study using occlusive patch tests (described earlier in this report), 39 subjects tested with 4, 8, 16, and 32% aqueous Sodium PCA were subsequently tested 3 months later with the same concentrations of Sodium PCA. The series of applications were made under occlusive patches to three sites on the back, two on the left and one on the right. One series was scored at 24 hours and the remaining two series at 48 hours. Two controls, distilled water and no treatment, were included in each series. No significant evidence of sensitization was observed. Of the two subjects who had significant reactions to the first exposure to Sodium PCA, the one that had the strongest reaction also had strong positive results after a second exposure. It was noted that this individual also had positive reactions at negative control sites. The other subject did not react to the second exposure to Sodium PCA (Ajinomoto Co., Inc. 1972).

The volunteers of this study were further tested in a photosensitization test. Following the last observation period of the sensitization test, the site of the patch series challenged for 24 hours was irradiated 24 hours later with UV light for 50 seconds (Patch Test 1). The site of one series challenged for 48 hours was irradiated similarly immediately after patch removal (Patch Test 2). The light source used was a Toshiba Fluorescent Lamp FL-20SEX, 2 pulse FL-20BLB X2, Total 80W (no wavelengths were reported). The remaining 48-hour challenged series received no radiation (Patch Test 3) and served as a control for Patch Test 2. A separate group of 18 male volunteers was treated in a similar manner except that they had never been sensitized with Sodium PCA (Patch Test 4). All of the sites were scored at 24-hour intervals after irradiation.

In Patch Tests 1 and 2, no increase was observed in irritancy after UV exposure as compared to the values obtained before UV exposure, rather the trend was dissipating. No significant differences between the test and control values were observed for either of these tests. In Patch Test 4, in which the subjects had not been sensitized to Sodium PCA, the results were similar to that observed in Patch Test 3. The investigators concluded that Sodium PCA was neither a phototoxic nor photosensitizing agent (Ajinomoto Co., Inc. 1972).

Skin Effects

A 2^2 factorial design was used to examine the effect of PCA and urea on transepidermal water loss (TEWL) (McCallion and Li Wan Po 1995). Two and 5% *w/w* PCA solutions in propylene glycol were used. TEWL was measured three times at five sites on four Caucasian female subjects. Baseline values were established. Increasing the PCA concentration from 2% to 5% *w/w* in the presence of both 10 and 20% urea resulted in a statistically significant increase in TEWL. Increasing the urea concentration from 10% to 20% *w/w* in the presence of 2% *w/w* PCA increased TEWL, but there was no additional influence on the effect of 5% PCA. The researchers stated that "the magnitude of effects of altering the concentration of urea depends on the concentration of PCA present and vice versa," indicating that PCA and urea were interactive.

SUMMARY

PCA and Sodium PCA are used as hair and skin conditioning agents in cosmetic formulations. Collectively, these compounds were used in 462 product formulations in 1996. One supplier recommends using these ingredients at a concentration range of 0.2–4%, not exceeding 5%. PCA and Sodium PCA are used in a variety of skin products at concentrations ranging from 0.001–2.5% and Sodium PCA 50% is used in bath preparations at 0.001% and in hair care products at concentrations ranging from 0.001–1%.

No by-products are reported in the production of PCA and Sodium PCA from glutamic acid and sodium glutamate, respectively. However, glutamic acid and sodium glutamate are possible impurities.

PCA is a naturally occurring component of mammalian tissue. PCA (and Sodium Lactate) constitute the most hygroscopic fraction of the stratum corneum. In general, the major biochemical pathway by which it is formed involves the catalysis of γ-glutamyl amino acids by γ-glutamyl cyclotransferase.

The percutaneous absorption of 5, 10, and 20% Sodium PCA through fresh human cadaver skin in a 24-hour period was 5.97, 6.78, and 5.89%, respectively. PCA was present in the plasma and brain of rats following oral administration. In studies with rabbits and mice, it was reported that PCA was metabolized into glutamic acid and γ-aminobutyric acid. A study using dogs reported that of the 70% of the oral dose absorbed, 30% was eliminated unchanged in the urine and the remainder was converted to urea. PCA given subcutaneously was also rapidly metabolized in mice.

The oral LD_{50} of Sodium PCA was 10.4 g/kg for male mice and >2.0 g/kg for a 50% solution in a study with rats. No adverse effects were observed in either a short-term study using rats fed 1.5% PCA or in subchronic studies with rats fed diets containing up to 8% PCA. In a study using mice, PCA was neurotoxic when injected intrastriatally. However, no effects were observed in a similar study with rats or after oral administration to mice.

No phototoxic effects were observed in guinea pigs treated topically with 1% aqueous Sodium PCA.

Sodium PCA was nonirritating when applied to the skin of guinea pigs and rabbits at concentrations up to 50%. No evidence of dermal sensitization was observed when guinea pigs were induced with 2–50% aqueous Sodium PCA and challenged with 5% aq. Sodium PCA. Sodium PCA was noncomedogenic in rabbits.

No ocular irritation was observed when 50% aqueous solutions of Sodium PCA was instilled into the conjunctival sac of the eye of rabbits.

PCA and Sodium PCA were not mutagenic in a *Salmonella* mutagenicity assay with or without metabolic activation, and PCA was not considered clastogenic in a chromosome damage assay.

In a clinical study of dermal irritation using open patch test methods on various sites of the body, 2 of 13 volunteers had reactions to 6.25% Sodium PCA applied to their backs and 3 volunteers developed erythema when concentrations of 12.5% Sodium PCA and greater were applied. These reactions disappeared within 30 minutes. No reactions were observed when Sodium PCA was applied to the skin of the forehead, cheek, or neck.

In another study, no significant irritation was observed when 46 volunteers were treated with 30% Sodium PCA using open patch test methods. Negative results were also obtained when 46 volunteers were tested with concentrations up to 32% Sodium PCA using occlusive patches. Provocative tests of 0.2% Sodium PCA using occlusive patches were also negative.

A formulation containing 2.0% Sodium PCA was negative in a minicumulative irritation test.

Clinical studies using 39 subjects indicated that 32% aqueous Sodium PCA is neither a sensitizer nor a photosensitizer. A maximization test of a cosmetic formulation containing 2.0% Sodium PCA was also negative.

In a 2^2 factorial design study, TEWL was significantly increased when PCA concentrations were increased from 2 to 5% in the presence of 10 and 20% urea. Increasing the concentration of urea in the presence of 2% also increased TEWL; the presence of 5% PCA did not have an additional influence. PCA and urea were interactive.

DISCUSSION

Upon review of the data included in this report, the CIR Expert Panel was concerned that developmental toxicity data were absent. A safety assessment could be completed, however, if PCA was found not to significantly penetrate the skin. Data were made available indicating that the amount of exogenously applied PCA absorbed through the skin was on the order of 1% of the applied dose, but that up to 5% was distributed between the dermis and epidermis.

Concern was expressed over the potential that the PCA adsorbed in the dermis and epidermis would eventually move across the skin and result in a cumulative penetration that could be significant. This concern was mitigated by the low actual penetration through the skin over a 24-hour period and the recognition that PCA is naturally resident in the skin. Additionally, it was noted that adverse effects were absent in a 26-week oral study. With these factors considered, the Expert Panel concluded that the extent of penetration was not significant and that developmental toxicity data were not critical to completion of the safety assessment.

The Expert Panel also recognized that although Sodium PCA was reported to be used in aerosol products, there was a lack of inhalation toxicity data. The Expert Panel noted that PCA is structurally similar to 4-hydroxy-L-proline, a major component of mammalian collagen. Also important was the minimal, transient ocular irritation produced by 50% Sodium PCA, which is used in hair sprays. The Expert Panel considered that such a compound, then, is unlikely to elicit a serious toxicological effect if inhaled as a result of an exposure to hair spray. Based on the structure of the ingredient and the existing data included in this report, the Expert Panel did not envision that Sodium PCA would be a respiratory irritant and therefore did not require inhalation toxicity data to make a determination of safety.

CONCLUSION

On the basis of the animal and clinical data presented in this report, the CIR Expert Panel concludes that PCA and Sodium PCA are safe as presently used in cosmetic formulations. These ingredients should not be used in cosmetic products containing nitrosating agents.

REFERENCES

Ajinomoto Co., Inc. 1972. Human skin tests of PCA-NA (Sodium DL-2-pyrrolidone-5-carboxylate). Technical bulletin AJD-7201. Unpublished data submitted by CTFA. 37 pages.[2]

Ajinomoto Co., Inc. 1992. *Salmonella* mutagenicity assay of PCA and PCA-Na. Protocol number 9209, April 7. Unpublished data submitted by CTFA. 3 pages.[2]

Ajinomoto Co., Inc. 1994a. Ajinomoto Co.'s humectant Ajidew. Unpublished data submitted by CTFA. 21 pages.[2]

Ajinomoto Co., Inc. 1994b. Ajidew—Supplementary safety evaluations on animals. Technical Bulletin AJD-8002. Unpublished data submitted by CTFA. 14 pages.[2]

Ajinomoto USA, Inc. 1995. Correspondence addressing recommended concentration of use and chemical characterization data. Unpublished data submitted by CTFA. 2 pages.[2]

Bousquet, E., V. Guarcello, M. C. Morale, and V. Rizza. 1983. Analysis of 5-pyrrolidone-2-carboxylate ester by reverse phase high-performance liquid chromatography. *Anal. Biochem.* 131:135–140.

Budavari, S., ed. 1989. *The Merck index. An encyclopedia of chemicals, drugs, and biologicals*, 11th ed., 1272–1273. Rahway, NJ: Merck & Co.

Caccia, S., P. Ghezzi, S. Garattini, M. Salmona, Y. Takasaki, and K. Torii. 1983. Pyroglutamate kinetics and neurotoxicity studies in mice. *Toxicol. Lett.* 16:225–229.

Centre International de Toxicologie. 1990. Assay of the potential acute toxicity—LD50 of Nalidone. Unpublished data submitted by Barnet Products Corp. 2 pages.[2]

Chanal, J. L., M. Audran, M. T. Sicard, and M. Briley. 1988. Brain penetration of orally administered sodium pyroglutamate. *J. Pharm. Pharmacol.* 40:584–585.

Cosmetic, Toiletry, and Fragrance Association (CTFA). 1990. 4-Day mini-cum irritancy test results of a formulation containing 2.0% Sodium PCA. Unpublished data submitted by CTFA. 1 page.[2]

CTFA. 1995. Product use concentration information for PCA and Sodium PCA; memorandum dated August 8. Submission of unpublished data by CTFA. 4 pages.[2]

DeLapp, N. W., and D. K. Dieckman. 1977. Biosynthesis of pyrrolidone carboxylic acid in hairless mouse epidermis. *J. Invest. Dermatol.* 68:293–298.

Food and Drug Administration (FDA). 1984. Cosmetic product formulation and frequency of use data. *FDA database*. Washington, DC: FDA.

FDA. 1992. Modification in voluntary filing of cosmetic product ingredient and cosmetic raw material composition statements. *Federal Register* 57:3128–3130.

FDA. 1996. Frequency of use of cosmetic ingredients. *FDA database*. Washington, DC: FDA.

Greenberg, L. D., and C. L. Schmidt. 1936. On the fate of *l*-pyrrolidone carboxylic acid in the dog and rat. *Univ. Calif. Publ. Physiol.* 8:129–134.

Hsu, T., and A. Meister. 1985. Metabolism *in vivo* of 5-oxo-L-proline and its inhibition by analogs of 5-oxo-L-proline. *Methods. Enzymol.* 113:468–471.

Huntingdon Life Sciences. 1996. DL-2-Pyrrolidone-5-Carboxylic Acid: An *in vitro* test for induction of chromosome damage: Cytogenetic study in cultured human peripheral lymphocytes. Final Report No. 96/AIN001/0104. Unpublished data submitted by CTFA. 37 pages.[2]

Ishii, H., T. Fujimoto, K. Ninomiya, and K. Torii. 1992. Toxicity study of sodium L-2-pyrrolidone-5-carboxylate administrated to rats in diet for 13 and 26 weeks. *Iyakuhin Kenkyu* 23:717–736.

Ivy Laboratories. 1991. The determination of the contact-sensitizing potential of four materials by means of the maximization test. 12G/95634-14 containing 2.0% Sodium PCA (0642). Unpublished data submitted by CTFA. 12 pages.[2]

Lange, W. E., and E. F. Carey. 1966. Metabolism of ^{14}C-labeled glutamic acid and pyroglutamic acid in animals. *J. Pharm. Sci.* 55:1147–1149.

Larmi, E., A. Lahti, and M. Hannuksela. 1989. Immediate contact reactions to benzoic acid and the sodium salt of pyrrolidone carboxylic acid. Comparison of various skin sites. *Contact. Derm.* 20:38–40.

Lin, J. K., C. S. Shieh, and T. C. Tung. 1971. Studies on pyroglutamic acid. I. Preparation, estimation and physicochemical properties of pyroglutamic acid. Taiwan I. *Hsueh Hui Tsa Chih* 70:73–79.

Marstein, S., E. Jellum, and L. Eldjarn. 1973. The concentration of pyroglutamic acid (2-pyrrolidone-5-carboxylic acid) in normal and psoriatic epidermis, determined on a microgram scale by gas chromatography. *Clin. Chim. Acta* 49:389–395.

McCallion, R., and A. Li Wan Po. 1995. *In vivo* evaluation of the effects of moisturisers on transepidermal water loss using factorial designs. *Int. J. Pharmaceut.* 113:247–255.

McGeer, E. G., and E. Singh. 1984. Neurotoxic effects of endogenous materials: Quinolinic acid, L-pyroglutamic acid, and thyroid releasing hormone (TRH). *Exp. Neurol.* 86:410–413.

Middleton, J. D. 1978. Sodium lactate as a moisturizer. *Cosmet. Toilet.* 93:85–86.

Pederson, S., and H. B. Lewis. 1944. The partition of urinary nitrogen after the oral administration of glutamic acid, pyrrolidonecarboxylic acid, proline, and hydroxyproline to rabbits. *J. Biol. Chem.* 154:705–712.

Ramakrishna, M., P. R. Krishnaswamy, and R. D. Rajagopal. 1970. Metabolism of pyrrolidonecarboxylic acid in the rat. *Biochem. J.* 118:895–897.

Rieke, G. K., A. D. Scarfe, J. F. Hunter. 1984. L-Pyroglutamate: An alternate neurotoxin for a rodent model of Huntington's disease. *Brain Res. Bull.* 13:443–456.

Shih, F. F. 1985. Analysis of glutamine, glutamic acid and pyroglutamic acid in protein hydrolysates by high-performance liquid chromatography. *J. Chromatogr.* 322:248–256.

Stehle, P., and P. Fürst. 1987. The occurrence of neurotoxic pyroglutamic acid in parenteral amino acid solutions. Specific determination by means of capillary isotachophoresis. *Clin. Chim. Acta* 169:323–328.

Surge Laboratory. 1995. *In vitro* percutaneous absorption of [^{14}C]-PCA in human skin. Study No. UCSF95SU07. Unpublished data submitted by CTFA. 32 pages.[2]

Tabachnick. J., and J. H. Labadie. 1970. Studies on the biochemistry of epidermis. IV. The free amino acids, ammonia, urea, and pyrrolidone carboxylic acid content of conventional and germ-free albino guinea pig epidermis. *J. Invest. Dermatol.* 54:24–31.

Tham, R., L. Nyström, and B. Holmstedt. 1968. Identification by mass spectrometry of pyroglutamic acid as a peak in the gas chromatography of human urine. *Biochem. Pharmacol.* 17:1735–1738.

Usines Chimiques D'Ivry-la-Bataille (UCIB). 1987. Comedogenic capacity of pyrolidone carboxylate sol aquesuse 50%. Unpublished data submitted by Barnet Products Corp. 6 pages.[2]

UCIB. 1989. Cutaneous primary irritation test in the rabbit of Nalidone. Unpublished data submitted by Barnet Products Corp. 5 pages.[2]

UCIB. 1990. Ocular tolerance test achieved on albino rabbits of Nalidone—Na Pyrrolidone carboxylate 50%. Unpublished data submitted by Barnet Products Corp. 5 pages.[2]

Van der Werf, P., and A. Meister. 1975. The metabolic formation and utilization of 5-oxo-L-proline (L-pyroglutamate, L-pyrrolidone carboxylate). *Adv. Enzymol. Relat. Areas Mol. Biol.* 43:519–556.

Wenninger, J. A., and G. N. McEwen, Jr., eds. 1997. *International cosmetic ingredient dictionary and handbook*, 7th ed. vol. 1, 924, 1298–1299. Washington, DC: CTFA.

Wilk, S., and M. Orlowski. 1973. The occurrence of free L-pyrrolidone carboxylic acid in body fluids and tissues. *FEBS. Lett.* 33:157–160.

Wolfersberger, M. G., and J. Tabachnick. 1973. Pyrrolidone carboxylic acid (pyroglutamic acid) in normal plasma. *Experentia* 29:346–347.

Wolfersberger, M. G., and J. Tabachnick. 1974. Enzymatic formation of L-pyrrolidone carboxylic acid in mammalian epidermis and other tissues. *J. Invest. Dermatol.* 62:587–590.

[2]Available for review: Director, Cosmetic Ingredient Review, 1101 17th Street, N.W., Suite 310, Washington, DC 20036, USA.

Wolfersberger, M. G., J. Tabachnick, B. S. Finkelstein, and M. Levin. 1973. L-Pyrrolidone carboxylic acid content in mammalian epidermis and other tissues. *J. Invest. Dermatol.* 60:278–281.

Yakuji Nippo, Ltd. 1994. *The comprehensive licensing standards of cosmetics by category 1994*. Tokyo: Yakuji Nippo, Ltd.

Yamada, T., M. Yamamoto, and A. Tanimura. 1981. Reaction of pyroglutamic acid with sodium nitrite. *J. Food Hyg. Soc. Japan* 22:404–408.

Zukowksi, J., M. Pawlowska, and D. W. Armstrong. 1992. Efficient enantioselective separation and determination of trace impurities in secondary amino acids (i.e., imino acids). *J. Chromatogr.* 623:33–41.

Concentration of Use by FDA Product Category – PCA and PCA Salts

PCA
Sodium PCA
Calcium PCA
Magnesium PCA
Potassium PCA

Ingredient	Product Category	Maximum Concentration of Use
PCA	Eyebrow pencil	0.00012%
PCA	Eyeliner	0.000012-0.87%
PCA	Eye shadow	0.00012-0.45%
PCA	Mascara	0.000012%
PCA	Perfume	0.0012%
PCA	Hair conditioners	0.0042-0.022%
PCA	Hair sprays aerosol pump spray	 0.0026-0.003% 0.01%
PCA	Rinses (noncoloring)	0.01%
PCA	Shampoos (noncoloring)	0.001-0.0022%
PCA	Tonics, dressings and other hair grooming aids	0.0041-0.49%
PCA	Blushers	0.099%
PCA	Face powders	0.000012-1.9%
PCA	Foundations	0.0012-0.15%
PCA	Lipstick	0.0012%
PCA	Makeup bases	0.00012%
PCA	Aftershave lotions	0.0012%
PCA	Shaving cream	0.0012%
PCA	Skin cleansing products	0.006%
PCA	Face and neck products not spray	 0.012-0.05%
PCA	Body and hand products not spray	 0.0012%
PCA	Moisturizing products not spray	 0.00024-0.1%
PCA	Night products not spray	 0.0043%
PCA	Other skin care preparations	0.0043-0.05% (leave-on)
Sodium PCA	Bubble baths	0.00005-0.013%
Sodium PCA	Other bath preparations	0.05%
Sodium PCA	Eye shadow	0.0001-0.22%
Sodium PCA	Eye lotion	0.05-2%
Sodium PCA	Eye makeup remover	0.57-1%
Sodium PCA	Other eye makeup preparations	0.5%
Sodium PCA	Colognes and toilet waters	0.0025%
Sodium PCA	Hair conditioners	0.005-0.5%
Sodium PCA	Hair sprays aerosol pump spray	 0.0002-0.052% 0.05-0.2%

Sodium PCA	Hair straighteners	1.5%
Sodium PCA	Permanent waves	0.13%
Sodium PCA	Rinses (noncoloring)	0.05-0.1%
Sodium PCA	Shampoos (noncoloring)	0.0023-1.5%
Sodium PCA	Tonics, dressings and other hair grooming aids	0.05-1%
Sodium PCA	Other hair preparations (noncoloring)	0.05-0.75%
Sodium PCA	Blushers	0.075-0.1%
Sodium PCA	Face powders	0.00585
Sodium PCA	Foundations	0.005-2%
Sodium PCA	Lipstick	0.0018%
Sodium PCA	Makeup bases	0.0017%
Sodium PCA	Nail creams and lotions	2.5%
Sodium PCA	Other manicuring preparations	0.25%
Sodium PCA	Bath soaps and detergents	0.005-1%
Sodium PCA	Other personal cleanliness products	1%
Sodium PCA	Aftershave lotions	0.5%
Sodium PCA	Shaving cream	0.5-0.95%
Sodium PCA	Skin cleansing	0.005-3%
Sodium PCA	Face and neck products not spray	0.05-0.75%
Sodium PCA	Body and hand products not spray	0.00005-1%
Sodium PCA	Foot products	0.05%
Sodium PCA	Moisturizing products not spray	0.1-2.5%
Sodium PCA	Night products not spray	0.05-1%
Sodium PCA	Paste masks and mud packs	0.05-0.25%
Sodium PCA	Skin fresheners	0.38-0.5%
Sodium PCA	Other skin care preparations	0.058-1%
Sodium PCA	Suntan products not spray	0.0003-0.25%
Sodium PCA	Indoor tanning preparations	0.022%
Sodium PCA	Other suntan preparations	0.013%
Calcium PCA	Eyeliner	0.01%
Calcium PCA	Eye shadow	0.1%
Calcium PCA	Eye lotion	0.04-0.05%
Calcium PCA	Blushers	0.1%
Calcium PCA	Face powders	0.1%
Calcium PCA	Foundations	0.1%
Calcium PCA	Lipstick	0.2%
Calcium PCA	Skin cleansing	0.001%
Calcium PCA	Face and neck products not spray	0.05-0.1%
Calcium PCA	Body and hand products not spray	0.04%
Calcium PCA	Moisturizing products not spray	0.04%
Calcium PCA	Skin fresheners	0.1%

Magnesium PCA	Face and neck products not spray	0.1%
Magnesium PCA	Moisturizing products not spray	0.1%
Magnesium PCA	Paste masks and mud packs	0.18%
Potassium PCA	Eye lotion	0.5%
Potassium PCA	Skin cleansing	0.085%
Potassium PCA	Face and neck products not spray	0.75%
Potassium PCA	Body and hand products not spray	0.05%
Potassium PCA	Moisturizing products not spray	0.005%
Potassium PCA	Paste masks and mud packs	0.013%

Information collected in 2014

Table prepared April 28, 2014